Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions
Semaglutide is a GLP-1 receptor agonist initially developed as a medication for diabetes
Improves mood and behavior
Physician Supervision Every protocol is designed, monitored, and adjusted by our board-certified physicians based on your labs, response, and health profile
US$ 23.11
US$ 27.63
US$ 24.32
US$ 23.11
US$ 23.91
